skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

ADMA Biologics Completes Acquisition of Biotest’s Therapy Business Unit Assets

Paul, Weiss represented ADMA Biologics, Inc. in its acquisition of the assets of Biotest Pharmaceuticals Corporation’s Therapy Business Unit. ADMA has assumed operational control of the assets and has formally commenced integration activities. As a result of this transaction, ADMA has acquired two U.S. Food and Drug Administration licensed products and two facilities for manufacturing and testing operations in Florida.  ADMA also received a cash capital contribution and was extended a subordinated loan by Biotest and an additional commitment from Biotest to invest in future ADMA equity financings.

The Paul, Weiss team included corporate partners Ariel Deckelbaum, Thomas de la Bastide, David Huntington and Ross Fieldston and counsel David Harris, Scott Grader and Patricia Vaz de Almeida; employee benefits partner Andrew Gaines; real estae partner Peter Fisch; intellectual property partner Claudine Meredith-Goujon; tax partner David Mayo; litigation partner Andrew Gordon and counsel Peter Jaffe; antitrust counsel Marta Kelly; and environmental counsel William O’Brien.

June 6, 2017

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy